What are the recommended dosages and dosing schedule for the Climara (estradiol) transdermal patch, and how should it be titrated for post‑menopausal women?

Climara Dosages for Postmenopausal Women

For postmenopausal women, Climara (estradiol transdermal patch) should be initiated at 50 μg/day (0.05 mg/day), applied once weekly, with the dose titrated up to 100 μg/day if needed for symptom control or bone protection. 1

Standard Dosing Regimen

Available Strengths and Application

• Starting dose: 50 μg/day patch applied once weekly
• Dose range: 25-100 μg/day, depending on clinical response
• Application frequency: Change patch every 7 days (once weekly)
• Application sites: Lower abdomen or buttocks (buttocks may provide 17% higher bioavailability) 2

Dose Titration Strategy

Initial 3-6 months:

• Start with 50 μg/day patch for most postmenopausal women 3
• For younger women with surgical menopause or premature ovarian insufficiency (POI), consider starting at 100 μg/day, then taper as tolerated 4
• Titrate upward if vasomotor symptoms persist or bone protection is inadequate

Available doses for titration:

• 25 μg/day (lowest dose, effective for bone protection) 5
• 50 μg/day (standard starting dose)
• 75 μg/day (intermediate dose) 6
• 100 μg/day (maximum typical dose) 3

Progestin Addition for Endometrial Protection

Women with an intact uterus require progestin supplementation to prevent endometrial hyperplasia 3:

Sequential Regimen (if withdrawal bleeding acceptable):

• Transdermal 17β-estradiol 50 μg/day continuously for 28 days
• Add oral micronized progesterone 200 mg daily (first choice) OR medroxyprogesterone acetate 10 mg daily for 12-14 days every 28 days 3

Continuous Combined Regimen (to avoid bleeding):

• Combined patches: 50 μg estradiol + 7 μg levonorgestrel daily, applied continuously without interruption 3
• Alternative: Continuous transdermal estradiol with daily oral progestin (micronized progesterone preferred) 3

Special Populations

Premature Ovarian Insufficiency (POI) / Young Women

• Dose: 50-100 μg/day transdermal patches 3
• Duration: Continue until average age of natural menopause (approximately 51 years) 7, 8
• Higher doses (100 μg/day) may be needed initially in younger women accustomed to higher endogenous estradiol levels 4

Pubertal Induction (Adolescents with POI)

For adolescents requiring pubertal induction, use a gradual escalation protocol over 24 months 3:

• 0-6 months: 1/8 of a 50 μg patch weekly (approximately 6.25 μg/day)
• 6-12 months: 1/4 of a 50 μg patch weekly (approximately 12.5 μg/day)
• 12-18 months: 1/2 of a 50 μg patch for 3-4 days, then 1/4 patch for remaining days
• 18-24 months: 1/2 of a 50 μg patch weekly (approximately 25 μg/day)
• >24 months: Full 50 μg patch weekly

Add progestin 2-3 years after starting estrogen or when breakthrough bleeding occurs 3.

Clinical Monitoring

Do NOT use serum FSH levels to monitor adequacy of estrogen replacement - FSH remains elevated despite adequate tissue effects 9. Instead:

• Titrate dose based on symptom response (vasomotor symptoms, vaginal dryness)
• Monitor bone mineral density with DEXA scanning for bone protection adequacy 9
• Consider measuring serum estradiol only when symptoms don't improve with dose escalation or when changing from oral to transdermal route 4

Key Advantages of Transdermal Route

Transdermal estradiol is preferred over oral formulations because it:

• Avoids first-pass hepatic metabolism, reducing effects on coagulation factors and SHBG 9, 4
• Provides more stable estradiol levels with less interindividual variability 9
• Lower risk of venous thromboembolism compared to oral estrogen 9, 8
• Particularly important in women with hypertension, hypertriglyceridemia, increased cholelithiasis risk, or cardiovascular risk factors 9

Common Pitfalls to Avoid

1. Don't underdose: The 25 μg/day patch, while effective for bone protection 5, may be insufficient for vasomotor symptom control in many women - start at 50 μg/day
2. Don't forget progestin: Women with a uterus absolutely require progestin supplementation 3
3. Don't use oral contraceptives for HRT in older postmenopausal women: Combined oral contraceptives contain ethinylestradiol, not physiologic 17β-estradiol, and carry higher thrombotic risk 3
4. Application site matters: Buttocks provide slightly higher bioavailability than abdomen 2, which may benefit women with end-of-week symptom breakthrough